Hvivo had net cash of £31.3 million on June 30th, almost double what it recorded on its books a year earlier. The group said it is debt free, has a robust net working capital, and has structured its contracts to be cash flow positive.
The company — which was formed when the group’s chairman Cathal Friel reversed his pharma services business of the same name into Dublin-listed drug clinical trials manager Venn Life Sciences — said the outlook for the business “remains extremely positive”. The board has increased its revenue guidance to £55 million for 2023 as well as increasing its EBITDA margin guidance to about 19 per cent for 2023.
Belgique Dernières Nouvelles, Belgique Actualités
Similar News:Vous pouvez également lire des articles d'actualité similaires à celui-ci que nous avons collectés auprès d'autres sources d'information.
Obesity drugs make Novo Nordisk Europe’s biggest companyCompany boosted by trial results showing weight loss drug also cuts risk of heart attack by 20%
La source: IrishTimes - 🏆 3. / 98 Lire la suite »